Value proposition

Transforming chronic wound care with breakthrough enzymatic technology

SolasCure is developing Aurase Wound Gel, its first investigational product, which is a single, effective and easy-to-use solution with strong IP, for all elements of chronic wound care in hospitals, clinics and homes. With over 100 million patients globally suffering from chronic wounds, debridement & wound bed preparation remain a huge unmet need in the face of rising prevalence and pressured health systems. Our mission is to overcome these challenges to transform chronic wound care.

Aurase Wound Gel consists of tarumase, a highly-specific fibrinolytic enzyme isolated & cloned from maggot saliva in a hydrogel for easy application on the wound. The product aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing.

Successful Phase IIa trials have demonstrated that Aurase Wound Gel has an excellent safety profile, is effective and pain free. The company is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds.

For more information, you can find our peer-reviewed clinical trial report here: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805

The importance of our innovative technology has been recognised with the following prestigious awards:
- Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024
- EIC Accelerator Grant (European Innovation Council), 2023
- Life Sciences Innovator (UK Department for Trade and Business), 2023
- EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022
- Winner 2019 URGO Mentorship Programme.

The Company was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company focused on harnessing biological diversity to develop innovative solutions.

SolasCure is headquartered in Cambridge, UK.

Visit us at www.solascure.com